Headlines Markets-Regulations 
pharmaphorum
AUGUST 21, 2020
New insights into smell and taste loss symptoms, artificial intelligence and further encouraging data from a vaccine candidate hit the headlines this week as the COVID-19 coronavirus pandemic continues. Here we highlight the biggest R&D, market access and digital coronavirus news of the past week.
pharmaphorum
DECEMBER 28, 2022
In pharma, multi-billion-dollar deals dominate M&A headlines, but most deals are far shorter of this range and generally lie between $10-$500 million. In turn, the acquiring company will help the novel drugs navigate the complexities and costs of regulations and benefit from market access and economies of scale.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JUNE 20, 2022
Paul Verdin, VP of consulting and analytics, and Andreas Hadjivasiliou, managing analyst at Evaluate, tell us about the company’s Orphan Drug Report 2022, which highlights activities within the orphan drug market and forecasts what the future of the industry holds based on data. Revising legislation. Positive projections.
pharmaphorum
FEBRUARY 25, 2021
Pfizer may have been making headlines with the COVID vaccine it developed with BioNTech, but it’s not the only infectious disease the big pharma is targeting. The FDA has granted a Priority Review, where the regulator aims to make a decision within six months instead of the standard 10 month period.
pharmaphorum
MARCH 8, 2022
The company didn’t conduct a conference call to discuss the findings, but took the unusual step of publishing a frequency asked questions (FAQ) document on the study, headlined with a non-committal statement about whether the data were “clinically meaningful.”
European Pharmaceutical Review
DECEMBER 13, 2022
Many excipients are manufactured outside of their major markets, ie, US, Japan and Europe; as such there should be transparency of the supply chain and proper flow of the necessary information. THE TRUTH PILL: The Myth of Drug Regulation in India. Cough syrup deaths expose lax drug regulation in India. The Lancet.
pharmaphorum
OCTOBER 23, 2020
Originally intended as a treatment for Ebola virus, remdesivir made headlines early on in the pandemic as the first drug to show significant improvements in recovery time in patients. The drug has already been approved by several other regulators across the world, including in the European Union and Japan.
Expert insights. Personalized for you.
105 
Let's personalize your content